This website uses cookies to ensure you get the best experience. By continuing to browse the site, you agree to our use of cookies.

Discover the

industry insights

and trends

[Insights]

Former Seagen CEO to Lead New Cancer Immunotherapy Efforts, $92M Secured to Advance Next-Gen ADCs, Clinical Trial Updates and more...

Alpha-9 Oncology Secures $175M for Radiopharmaceuticals, Alphina Therapeutics Welcomes New CEO, and Bicycle Therapeutics Advances Targeted Therapies, Series Investments, and more...

Abalos Therapeutics Appoints Gerben Moolhuizen as CEO, Gritstone Bio Files for Chapter 11 with $61.7M Cash, and Kiromic BioPharma Reports Promising Phase 1 Results for Deltace in Stage 4 NSCLC, Clinical Trial Updates, Layoffs, and more...

Topas Therapeutics Reports Positive Phase 2a Results for Celiac Disease Therapy, C4 Therapeutics Appoints New CSO, Gilead Withdraws Trodelvy After Bladder Cancer Trial Failure, Clinical Trial Updates, and more

Aktis Oncology Raises $175 Million for Targeted Cancer Therapies; Halda Therapeutics Appoints New CEO to Lead Innovative Cancer Trials; Relay Therapeutics' Workforce Reduction by 10% Amid Continued Program Advancement, Clinical Trial Updates, Series Investments, and more...

Astellas Gains European Approval for CLDN18.2-Targeted Therapy, Atavistik Bio Welcomes Dr. Mohammad Hirmand to Board, Merck's Keytruda-Favezelimab Combo Falls Short in MSS Colorectal Cancer Trial, Series Investments, Clinical Trial Updates, and more...

Kyverna CEO Change, Innovent's IBI363 Shows 65.6% DCR, and FDA Approves Novartis’s Kisqali with 25% Risk Reduction, Series Investments, Clinical Trial Updates, and more...

Career Consulting

You can find in this guide: Two Recruitment Strategies, The 7 main motivators of change to candidates, 12+ Examples of LinkedIn Social Ads, Framework for Social Media Writing, 6 Actionable Next Steps

PhoreMost Secures $12M for Oncology Expansion, Telix Advances Kidney Cancer Imaging, Oncternal Shuts Down Trials Amid Financial Struggles, Series Investments, and more...

Shape the future

Shape the future

Shape the future

Shape the future